Radiopharmaceuticals Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Radiopharmaceuticals</strong> <strong>Market</strong><br />
Siemens Healthineers is slated to remain the most dominant company in the global radiopharmaceuticals<br />
market, accounting for over 40% of global revenues. Due to participation of Siemens and companies such<br />
as Advanced Accelerator Applications (France), Bayer AG (Germany), IBA Radiopharma Solutions<br />
(Belgium) and Eckert & Zeigler (Germany), Western Europe’s radiopharmaceuticals market is also<br />
expected to expand progressively and close in on US$ 1,600 million valuation by the end of 2026.<br />
<strong>Radiopharmaceuticals</strong> – Scope for Application & End-use<br />
Favourable growth opportunities for radiopharmaceutical manufacturers from around the world are<br />
sited in therapeutic applications such as oncology, cardiology, neuroendocrinology, and neurology,<br />
among others.<br />
In 2017 and beyond, consumption of radiopharmaceuticals for oncological procedures will gain<br />
traction, registering revenue growth at 6% CAGR.<br />
On the other hand, radiopharmaceuticals consumed by neurological studies & treatment procedures<br />
will surge at the highest rate, surpassing US$ 700 million valuation by 2026-end.<br />
Another key insight offered in the report suggests that radiopharmaceuticals used by diagnostic<br />
imaging centres will increase over the forecast period.<br />
Click here to<br />
Order a free sample<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 6
Change language